Literature DB >> 10580567

Apoptosis, proliferation and NF-kappaB activation induced by agonistic Fas antibodies in the human myeloma cell line OH-2: amplification of Fas-mediated apoptosis by tumor necrosis factor.

M Børset1, H Hjorth-Hansen, A C Johnsen, C Seidel, A Waage, T Espevik, A Sundan.   

Abstract

Tumor necrosis factor (TNF) is known to be a growth factor for several myeloma cell lines. However, in the presence of the agonistic Fas antibody CH 11, TNF enhanced the level of apoptosis in cultures of the human myeloma cell line OH-2. This pro-apoptotic effect of TNF was explained at least in part by a TNF-mediated enhancement of Fas expression. TNF induces proliferation of OH-2 by activating nuclear transcription factor kappa-B (NF-kappaB). The proliferative effect of TNF on OH-2 cells was abrogated by CH11, but this was not caused by an inhibition of the translocation of NF-kappaB. On the contrary, CH11 could by itself activate NF-kappaB in OH-2 cells, and in the presence of an inhibitor of caspase-1 induce proliferation of the cells. The relationship between stimulation of TNF receptors and Fas and the level of NF-kappaB activation was also examined in three other myeloma cell lines. RPMI-8226 cells showed NF-kappaB activation by TNF, but contrary to OH-2, not by CH11. Unstimulated U-266 and JJN-3 cells had high levels of activated NF-kappaB. This shows that NFkappa-B is either constitutively activated or inducible in myeloma cells. Modulation of Fas expression and inhibition of NF-kappaB activation can potentially be of therapeutic importance in multiple myeloma.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10580567     DOI: 10.1111/j.1600-0609.1999.tb01138.x

Source DB:  PubMed          Journal:  Eur J Haematol        ISSN: 0902-4441            Impact factor:   2.997


  8 in total

1.  Correlation of sera TNF-alpha with percentage of bone marrow plasma cells, LDH, beta2-microglobulin, and clinical stage in multiple myeloma.

Authors:  Vladimir Jurisić; Milica Colović
Journal:  Med Oncol       Date:  2002       Impact factor: 3.064

2.  Antioxidant c-FLIP inhibits Fas ligand-induced NF-kappaB activation in a phosphatidylinositol 3-kinase/Akt-dependent manner.

Authors:  Anand Krishnan V Iyer; Neelam Azad; Siera Talbot; Christian Stehlik; Bin Lu; Liying Wang; Yon Rojanasakul
Journal:  J Immunol       Date:  2011-08-19       Impact factor: 5.422

3.  Promoter polymorphism of FASL confers protection against female-specific cancers and those of FAS impact the cancers divergently.

Authors:  Sateesh Reddy Nallapalle; Sarika Daripally; V T S Vidudala Prasad
Journal:  Tumour Biol       Date:  2014-12-04

4.  The Fas system confers protection against alveolar disruption in hyperoxia-exposed newborn mice.

Authors:  Quanfu Mao; Sravanthi Gundavarapu; Chintan Patel; Amy Tsai; Francois I Luks; Monique E De Paepe
Journal:  Am J Respir Cell Mol Biol       Date:  2008-06-27       Impact factor: 6.914

5.  Cellular FLICE-like inhibitory protein deviates myofibroblast fas-induced apoptosis toward proliferation during lung fibrosis.

Authors:  Regina Golan-Gerstl; Shulamit B Wallach-Dayan; Philip Zisman; Wellington V Cardoso; Ronald H Goldstein; Raphael Breuer
Journal:  Am J Respir Cell Mol Biol       Date:  2012-05-10       Impact factor: 6.914

6.  NFκB1 and NFκBIA polymorphisms are associated with increased risk for sporadic colorectal cancer in a southern Chinese population.

Authors:  Shunxin Song; Dianke Chen; Jiachun Lu; Jiawei Liao; Yanxin Luo; Zuli Yang; Xinhui Fu; Xinjuan Fan; Yisheng Wei; Lei Yang; Lei Wang; Jianping Wang
Journal:  PLoS One       Date:  2011-06-30       Impact factor: 3.240

7.  TNFR1 and TNFR2 regulate the extrinsic apoptotic pathway in myeloma cells by multiple mechanisms.

Authors:  H Rauert; T Stühmer; R Bargou; H Wajant; D Siegmund
Journal:  Cell Death Dis       Date:  2011-08-18       Impact factor: 8.469

8.  TNFα sensitizes neuroblastoma cells to FasL-, cisplatin- and etoposide-induced cell death by NF-κB-mediated expression of Fas.

Authors:  Koen Mo Galenkamp; Paulina Carriba; Jorge Urresti; Laura Planells-Ferrer; Elena Coccia; Joaquín Lopez-Soriano; Bruna Barneda-Zahonero; Rana S Moubarak; Miguel F Segura; Joan X Comella
Journal:  Mol Cancer       Date:  2015-03-19       Impact factor: 27.401

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.